Shoichi Maruyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoichi Maruyama has a total of 733 co-authors. Here are the top co-authors by number of shared publications:
Takahiro Imaizumi
Nagoya University Graduate School of Medicine Department of Nephrology 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi
18 shared publicationsTakayuki Katsuno
Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
17 shared publicationsSawako Kato
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
16 shared publicationsYoshinari Yasuda
Nagoya University Graduate School of Medicine Department of Nephrology/CKD Initiatives Nagoya
16 shared publicationsSeiichi Matsuo
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
15 shared publications- Takahiro Imaizumi
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan
15 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Open AccessHypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- Open Access
- 2 November 2026
- Published by Wiley in Nephrology
- Vol. 31 (11)
Current Status and Temporal Changes in Lupus Nephritis in Japan: Analysis of the Japan Renal Biopsy Registry
Aim: This study evaluated temporal changes in the clinical and histological features of lupus nephritis at first renal biopsy in Japan. Methods: This retrospective observational study used Japan Renal Biopsy Registry data. Patients undergoing their first renal biopsy in 2018–2021 were compared with a historical cohort from 2007 to 2012. Clinical characteristics and histological classes based on the International Society of Nephrology/Renal Pathology Society classification were compared. Results: The study included 331 patients in the historical cohort and 682 in the recent cohort. The recent cohort was older (median age, 42 vs. 37 years; p = 0.014), with a higher proportion aged 60 years or older (19.2% vs. 10.6%; p < 0.001). Histological class distribution differed significantly between cohorts. Class IV (±V) lesions were less frequent in the recent cohort (34.3% vs. 44.1%), whereas Class II and Class III (±V) lesions were numerically more frequent. The lower odds of Class IV (±V) lesions persisted after adjustment for age group (odds ratio, 0.676; 95% confidence interval, 0.516–0.886; p = 0.005). Amongst patients with Class III/IV lesions, pure Class III lesions were more frequent and pure Class IV lesions were less frequent in the recent cohort. Conclusion: The recent first‐biopsy cohort was older and had a lower proportion of Class IV (±V) lesions than the historical cohort, even after age adjustment. These findings suggest temporal changes in LN in Japan, although the greater proportion of missing histological classification data in the historical cohort should be considered when interpreting the histological differences.
- 2 November 2026
- Published by Wiley in Nephrology
- Vol. 31 (11)
Open AccessCurrent Status and Temporal Changes in Lupus Nephritis in Japan: Analysis of the Japan Renal Biopsy Registry
Aim: This study evaluated temporal changes in the clinical and histological features of lupus nephritis at first renal biopsy in Japan. Methods: This retrospective observational study used Japan Renal Biopsy Registry data. Patients undergoing their first renal biopsy in 2018–2021 were compared with a historical cohort from 2007 to 2012. Clinical characteristics and histological classes based on the International Society of Nephrology/Renal Pathology Society classification were compared. Results: The study included 331 patients in the historical cohort and 682 in the recent cohort. The recent cohort was older (median age, 42 vs. 37 years; p = 0.014), with a higher proportion aged 60 years or older (19.2% vs. 10.6%; p < 0.001). Histological class distribution differed significantly between cohorts. Class IV (±V) lesions were less frequent in the recent cohort (34.3% vs. 44.1%), whereas Class II and Class III (±V) lesions were numerically more frequent. The lower odds of Class IV (±V) lesions persisted after adjustment for age group (odds ratio, 0.676; 95% confidence interval, 0.516–0.886; p = 0.005). Amongst patients with Class III/IV lesions, pure Class III lesions were more frequent and pure Class IV lesions were less frequent in the recent cohort. Conclusion: The recent first‐biopsy cohort was older and had a lower proportion of Class IV (±V) lesions than the historical cohort, even after age adjustment. These findings suggest temporal changes in LN in Japan, although the greater proportion of missing histological classification data in the historical cohort should be considered when interpreting the histological differences.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- Open Access
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Tamibarotene, a Stromal-Targeting Retinoid, Plus Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer (MIKE-1): A Multicentre, Single-Arm, Open-Label, Phase 1/2 Trial
Background: In pancreatic ductal adenocarcinoma (PDAC), desmoplastic stroma limits drug delivery and contributes to therapeutic resistance. First-line gemcitabine plus nab-paclitaxel (GnP) has historically achieved an objective response rate (ORR) of about 23%, and no stromal-targeting approach has yet altered the first-line standard of care. Tamibarotene (AM80), a retinoid, induces tumour-restraining cancer-associated fibroblasts (rCAFs) in preclinical models, a reprogramming effect associated with improved intratumoural chemotherapy delivery. We evaluated tamibarotene plus GnP in patients with unresectable PDAC. Methods: MIKE-1 was an investigator-initiated, open-label, single-arm phase 1/2 trial in previously untreated unresectable PDAC. Phase 1, conducted at Nagoya University Hospital, used a 3+3 dose escalation design; phase 2 was undertaken at Nagoya University Hospital and University of Tokyo Hospital. Primary endpoints were determination of the recommended phase 2 dose in phase 1 and investigator-assessed confirmed ORR per RECIST version 1·1 in phase 2. Findings: Between March 2022 and April 2025, 60 patients were enrolled and 59 started treatment. At data cutoff (2 October 2025; median follow-up 12·7 months), the confirmed ORR in phase 2 (n=42; tamibarotene 8 mg/day on days 1–14 plus GnP) was 50·0% (21/42; 90% CI 36·5–63·5; p<0·001 vs the prespecified historical 23% threshold), and the disease control rate was 85·7% (36/42). Median progression-free survival was 11·3 months, median overall survival was not reached, and 12-month overall survival was 86·9% (95% CI 71·0–94·4). Interstitial lung disease (ILD) occurred in seven (16·7%) of 42 patients; all improved or resolved, and no grade 5 treatment-related adverse events occurred. In 12 phase 1/2 paired-biopsy patients, Xenium spatial transcriptomics showed an on-treatment shift away from myofibroblastic CAFs (myCAFs) towards rCAFs. Interpretation: Tamibarotene plus GnP exceeded the prespecified ORR threshold, with paired-biopsy increases in stromal Meflin and a myCAF-to-rCAF shift consistent with stromal reprogramming. A randomised trial versus GnP alone, with prospective ILD monitoring, is warranted.
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTamibarotene, a Stromal-Targeting Retinoid, Plus Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer (MIKE-1): A Multicentre, Single-Arm, Open-Label, Phase 1/2 Trial
Background: In pancreatic ductal adenocarcinoma (PDAC), desmoplastic stroma limits drug delivery and contributes to therapeutic resistance. First-line gemcitabine plus nab-paclitaxel (GnP) has historically achieved an objective response rate (ORR) of about 23%, and no stromal-targeting approach has yet altered the first-line standard of care. Tamibarotene (AM80), a retinoid, induces tumour-restraining cancer-associated fibroblasts (rCAFs) in preclinical models, a reprogramming effect associated with improved intratumoural chemotherapy delivery. We evaluated tamibarotene plus GnP in patients with unresectable PDAC. Methods: MIKE-1 was an investigator-initiated, open-label, single-arm phase 1/2 trial in previously untreated unresectable PDAC. Phase 1, conducted at Nagoya University Hospital, used a 3+3 dose escalation design; phase 2 was undertaken at Nagoya University Hospital and University of Tokyo Hospital. Primary endpoints were determination of the recommended phase 2 dose in phase 1 and investigator-assessed confirmed ORR per RECIST version 1·1 in phase 2. Findings: Between March 2022 and April 2025, 60 patients were enrolled and 59 started treatment. At data cutoff (2 October 2025; median follow-up 12·7 months), the confirmed ORR in phase 2 (n=42; tamibarotene 8 mg/day on days 1–14 plus GnP) was 50·0% (21/42; 90% CI 36·5–63·5; p<0·001 vs the prespecified historical 23% threshold), and the disease control rate was 85·7% (36/42). Median progression-free survival was 11·3 months, median overall survival was not reached, and 12-month overall survival was 86·9% (95% CI 71·0–94·4). Interstitial lung disease (ILD) occurred in seven (16·7%) of 42 patients; all improved or resolved, and no grade 5 treatment-related adverse events occurred. In 12 phase 1/2 paired-biopsy patients, Xenium spatial transcriptomics showed an on-treatment shift away from myofibroblastic CAFs (myCAFs) towards rCAFs. Interpretation: Tamibarotene plus GnP exceeded the prespecified ORR threshold, with paired-biopsy increases in stromal Meflin and a myCAF-to-rCAF shift consistent with stromal reprogramming. A randomised trial versus GnP alone, with prospective ILD monitoring, is warranted.
- 10 July 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-27
Kidney and Cardiovascular Outcomes by CKD stage and etiology of CKD: A Randomly Selected Nationwide Prospective Multicenter Cohort Study in Japan (Reach-J Study)
Introduction: Countermeasures against kidney disease are recognized worldwide as an important health management issue. Accurate identification and examination of the primary diseases that lead to end-stage kidney disease are crucial. Methods: We established the REACH-J cohort, a nationwide chronic kidney disease (CKD) cohort using a random sampling method including 31 medical institutions. Patients with CKD stage G3b–G5 were enrolled and completed surveys on lifestyle and medical visits; institutions provided data on patient medical history with a 5-year follow-up. Results: Among 2,249 patients (mean age, 69.1 ± 12.6 years), primary CKD etiologies were diabetic kidney disease (DKD; 24.5%), nephrosclerosis (NSc; 24.4%), polycystic kidney disease (PKD; 5.8%), and others (45.3%). Event rates (per 100 person-years) were 3.0 for all-cause mortality, 2.0 for pre-kidney replacement therapy (KRT) death, and 8.4 for KRT initiation. DKD has the highest KRT initiation patients stage G3b, whereas PKD had the highest rate in stages G4/G5. NSc consistently had the lowest KRT initiation rates. Mortality was highest in DKD in stage G3b, followed by Nsc. Kaplan–Meier analysis showed an early KRT initiation rate in DKD, later surpassed by PKD. Across etiologies, higher proteinuria predicted poorer renal outcomes, while cardiovascular and mortality rates did not differ by proteinuria stage. Conclusions: Although DKD is the leading cause of end-stage kidney disease worldwide, PKD most commonly led to dialysis in patients with CKD stages 4–5. In contrast, non-proteinuric NSc conferred a very low risk of end-stage kidney disease even in advanced CKD (G3b–G5).
- 10 July 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-27
Kidney and Cardiovascular Outcomes by CKD stage and etiology of CKD: A Randomly Selected Nationwide Prospective Multicenter Cohort Study in Japan (Reach-J Study)
Introduction: Countermeasures against kidney disease are recognized worldwide as an important health management issue. Accurate identification and examination of the primary diseases that lead to end-stage kidney disease are crucial. Methods: We established the REACH-J cohort, a nationwide chronic kidney disease (CKD) cohort using a random sampling method including 31 medical institutions. Patients with CKD stage G3b–G5 were enrolled and completed surveys on lifestyle and medical visits; institutions provided data on patient medical history with a 5-year follow-up. Results: Among 2,249 patients (mean age, 69.1 ± 12.6 years), primary CKD etiologies were diabetic kidney disease (DKD; 24.5%), nephrosclerosis (NSc; 24.4%), polycystic kidney disease (PKD; 5.8%), and others (45.3%). Event rates (per 100 person-years) were 3.0 for all-cause mortality, 2.0 for pre-kidney replacement therapy (KRT) death, and 8.4 for KRT initiation. DKD has the highest KRT initiation patients stage G3b, whereas PKD had the highest rate in stages G4/G5. NSc consistently had the lowest KRT initiation rates. Mortality was highest in DKD in stage G3b, followed by Nsc. Kaplan–Meier analysis showed an early KRT initiation rate in DKD, later surpassed by PKD. Across etiologies, higher proteinuria predicted poorer renal outcomes, while cardiovascular and mortality rates did not differ by proteinuria stage. Conclusions: Although DKD is the leading cause of end-stage kidney disease worldwide, PKD most commonly led to dialysis in patients with CKD stages 4–5. In contrast, non-proteinuric NSc conferred a very low risk of end-stage kidney disease even in advanced CKD (G3b–G5).
- Open Access
- 8 July 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104293
Iron-Catalyzed Oxidative Stress Reveals an Exposome-Related Ferroptosis-Resistant Karyomegalic Niche in BRCA1-Linked Renal Carcinogenesis
- 8 July 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104293
Open AccessIron-Catalyzed Oxidative Stress Reveals an Exposome-Related Ferroptosis-Resistant Karyomegalic Niche in BRCA1-Linked Renal Carcinogenesis
- Open Access
- 30 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (8)
Key predictors of mortality in profound hyponatremia beyond the correction rate
Background: Current guidelines for hyponatremia recommend slow sodium correction; however, recent large-scale observational studies have associated slow correction with increased mortality. The association between correction rate and mortality can be influenced by numerous factors, including comorbidities, overall condition, and treatment interventions, but this complex interplay remains unclear. We aimed to clarify this association by developing interpretable machine learning models using detailed clinical features. Methods: We included 546 patients with serum sodium ≤120 mEq/L, collected clinical features through chart review, and developed four machine learning models to predict in-hospital mortality. The best-performing model, selected by the area under the receiver operating characteristic curve (ROC-AUC), was interpreted using SHapley Additive exPlanations (SHAP) to quantify each feature’s contribution to mortality prediction. Results: In-hospital mortality was 18%. The random forest model demonstrated the best predictive performance (ROC-AUC = 0.907; 95% CI, 0.832–0.965). SHAP analysis revealed that the most influential predictors were baseline characteristics reflecting underlying illness severity: serum albumin, C-reactive protein, Charlson Comorbidity Index, and metastatic malignancy; their predictive effects were consistent across correction rates. Among treatment-related features, intravenous fluid choice and sodium monitoring frequency had a greater predictive impact than correction rate. Although slower correction was associated with higher mortality, the correction rate ranked 14th among all 59 features in predictive importance. Conclusions: In profound hyponatremia, multiple key predictors of mortality exist beyond the correction rate. These findings suggest that the observed association between slow correction and higher mortality may not be causal but rather an epiphenomenon driven by underlying illness severity and treatment intensity.
- 30 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (8)
Open AccessKey predictors of mortality in profound hyponatremia beyond the correction rate
Background: Current guidelines for hyponatremia recommend slow sodium correction; however, recent large-scale observational studies have associated slow correction with increased mortality. The association between correction rate and mortality can be influenced by numerous factors, including comorbidities, overall condition, and treatment interventions, but this complex interplay remains unclear. We aimed to clarify this association by developing interpretable machine learning models using detailed clinical features. Methods: We included 546 patients with serum sodium ≤120 mEq/L, collected clinical features through chart review, and developed four machine learning models to predict in-hospital mortality. The best-performing model, selected by the area under the receiver operating characteristic curve (ROC-AUC), was interpreted using SHapley Additive exPlanations (SHAP) to quantify each feature’s contribution to mortality prediction. Results: In-hospital mortality was 18%. The random forest model demonstrated the best predictive performance (ROC-AUC = 0.907; 95% CI, 0.832–0.965). SHAP analysis revealed that the most influential predictors were baseline characteristics reflecting underlying illness severity: serum albumin, C-reactive protein, Charlson Comorbidity Index, and metastatic malignancy; their predictive effects were consistent across correction rates. Among treatment-related features, intravenous fluid choice and sodium monitoring frequency had a greater predictive impact than correction rate. Although slower correction was associated with higher mortality, the correction rate ranked 14th among all 59 features in predictive importance. Conclusions: In profound hyponatremia, multiple key predictors of mortality exist beyond the correction rate. These findings suggest that the observed association between slow correction and higher mortality may not be causal but rather an epiphenomenon driven by underlying illness severity and treatment intensity.
- Open Access
- 15 June 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (3)
Rapid versus conventional glucocorticoid tapering in pure membranous LN: a multicentre retrospective study
Objectives: While recent guidelines recommend early glucocorticoid (GC) tapering for LN, supporting evidence for pure membranous LN remains limited. The present study investigated the impact of rapid GC tapering on renal outcomes in this population. Methods: We performed a multicentre retrospective study across 16 centres in Japan, including 67 patients with biopsy-proven pure membranous LN who initiated GC therapy between 2003 and 2023. Patients were classified into rapid tapering (GC dose ≤7.5 mg/day at 6 months) and conventional tapering (>7.5 mg/day at 6 months) groups. The primary endpoint was the partial renal response (PRR) at 12 months. Secondary endpoints included the complete renal response (CRR), relapse and severe adverse events (SAEs). Adjusted risk ratios (aRRs) were estimated using modified Poisson regression models for failure to achieve PRR/CRR. Results: Fifteen patients underwent rapid tapering and 52 conventional tapering. Baseline characteristics were generally comparable. At 12 months, PRR was achieved in 85.7% of the rapid group and 84.3% of the conventional group (aRR for failure 1.04; 95% CI 0.17–6.39). CRR rates at 12 months were 64.3% and 56.9%, respectively (aRR for failure 0.90; 95% CI 0.40–2.02). At 24 months, PRR and CRR did not differ statistically between groups. Relapse occurred in 20.0% versus 7.7% (P = 0.185). No SAEs were reported in the rapid group, while three occurred in the conventional group. Conclusions: Rapid GC tapering to ≤7.5 mg/day at 6 months appeared feasible in a subset of patients with pure membranous LN, but the findings are preliminary and should be interpreted cautiously because of the small rapid-taper group and imprecise estimates.
- 15 June 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (3)
Open AccessRapid versus conventional glucocorticoid tapering in pure membranous LN: a multicentre retrospective study
Objectives: While recent guidelines recommend early glucocorticoid (GC) tapering for LN, supporting evidence for pure membranous LN remains limited. The present study investigated the impact of rapid GC tapering on renal outcomes in this population. Methods: We performed a multicentre retrospective study across 16 centres in Japan, including 67 patients with biopsy-proven pure membranous LN who initiated GC therapy between 2003 and 2023. Patients were classified into rapid tapering (GC dose ≤7.5 mg/day at 6 months) and conventional tapering (>7.5 mg/day at 6 months) groups. The primary endpoint was the partial renal response (PRR) at 12 months. Secondary endpoints included the complete renal response (CRR), relapse and severe adverse events (SAEs). Adjusted risk ratios (aRRs) were estimated using modified Poisson regression models for failure to achieve PRR/CRR. Results: Fifteen patients underwent rapid tapering and 52 conventional tapering. Baseline characteristics were generally comparable. At 12 months, PRR was achieved in 85.7% of the rapid group and 84.3% of the conventional group (aRR for failure 1.04; 95% CI 0.17–6.39). CRR rates at 12 months were 64.3% and 56.9%, respectively (aRR for failure 0.90; 95% CI 0.40–2.02). At 24 months, PRR and CRR did not differ statistically between groups. Relapse occurred in 20.0% versus 7.7% (P = 0.185). No SAEs were reported in the rapid group, while three occurred in the conventional group. Conclusions: Rapid GC tapering to ≤7.5 mg/day at 6 months appeared feasible in a subset of patients with pure membranous LN, but the findings are preliminary and should be interpreted cautiously because of the small rapid-taper group and imprecise estimates.